ClinicalTrials.gg
CompletedNCT02238119Updated Sep 12, 2014

Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Tiotropium + formoterol combination and Tiotropium in Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2014-09-12.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. tiotropium · Pulmonary Disease, Chronic Obstructive.

Enrollment
72nd of 105
74 · median 131
Started
2002
with 14 others
Phase 2
10 of 105
none open now
Registered
79th of 105
by date
Lead sponsor
54 of 105
Boehringer Ingelheim

Among the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive, this one is the 72nd largest by enrollment, is one of 15 that started in 2002, is one of 10 in phase 2, and was the 79th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About tiotropium

tiotropium: first FDA approval 2004 (SPIRIVA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 105 studies testing tiotropium in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

Study to evaluate the lung function response to the free once-daily combination of tiotropium + formoterol compared to formoterol BID and tiotropium QD

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients had to sign an consistent with International Conference on Harmonization Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial, which included medication washout and restrictions
  2. All patients had to have a diagnosis of and had to meet the following spirometric criteria:

    • Patients had to have relatively stable moderate to severe airway obstruction with an ≤ 60% of predicted normal and FEV1 ≤ 70% of FVC (Visits 1 and 2)
  3. Male or female patients 40 years of age or older
  4. Patients had to be current or ex-smokers with a smoking history of more than 10 pack-years (Patients who had never smoked cigarettes had to be excluded)
  5. Patients had to be able to perform technically acceptable pulmonary function tests and had to be able to maintain records (Patient Daily Diary Record) during the study period as required in the protocol
  6. Patients had to be able to inhale medication in a competent manner from the HandiHaler® device, the Blue Inhaler device and from a metered dose inhaler (MDI)

Exclusion criteria

Exclusion Criteria:

  1. Patients with significant diseases other than had to be excluded. A significant disease was defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study
  2. Patients with abnormal baseline haematology, blood chemistry, or urinalysis if the abnormality defined a disease listed as an exclusion criterion
  3. All patients with an serum glutamate oxaloacetate transaminase () > 80 IU/L, serum glutamate pyruvate transaminase (SGPT) > 80 IU/L, > 17 μmol/L or creatinine > 110 μmol/L (males) / 95 μmol/L (females) had to be excluded regardless of clinical condition
  4. Patients with a recent history (i.e., six months or less) of myocardial infarction
  5. Patients with any cardiac arrhythmia requiring drug therapy or who had been hospitalised for heart failure within the past three years
  6. Patients with a history of cancer within the last five years. Patients with treated basal cell carcinoma were allowed
  7. Patients with known symptomatic prostatic hypertrophy or bladder neck obstruction.

    Patients with prostatic hypertrophy controlled by medication were allowed

  8. Patients with known narrow-angle glaucoma
  9. Patients with a history of asthma, allergic rhinitis or who had a total blood eosinophil count ≥600 mm3
  10. Patients with a history of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis
  11. Patients with known active tuberculosis
  12. Patients with a history of and/or active significant alcohol or drug abuse. See exclusion criterion No. 1.
  13. Patients who had undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons had to be evaluated as per exclusion criterion No. 1
  14. Patients who completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1)
  15. Patients who regularly used daytime oxygen therapy
  16. Patients who had taken an drug within one month or six half lives (whichever is greater) prior to Screening Visit (Visit 1)
  17. Patients who were treated with beta-blocker medications. Note: cardioselective beta blocker eye medications (e.g. Betoptic®) for treatment of non-narrow angle glaucoma were allowed
  18. Patients who were treated with oral beta-adrenergics
  19. Patients who were treated with cromolyn sodium or nedocromil sodium
  20. Patients who were treated with antihistamines (H1 receptor antagonists), antileukotrienes or leukotriene receptor antagonists for asthma or excluded allergic conditions. See exclusion criterion No. 9
  21. Patients using oral medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day
  22. Patients with known to anticholinergic drugs, beta-adrenergics, lactose or any other components of the inhalation capsule delivery systems
  23. Pregnant or nursing women or women of not using a medically approved means of for the previous 3 months (i.e. oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g., Norplant®)
  24. Patients with previous participation (receipt of randomised treatment) in this study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
74 participants (actual)

Study arms

  • Experimental
    tiotropium + formoterol

    Drug: Tiotropium + formoterol combination

  • Active comparator
    tiotropium

    Drug: Tiotropium

  • Active comparator
    formoterol

    Drug: Formoterol

Interventions

06

What researchers measure

Primary outcomes

  1. Change in area under the curve from pre-dose to 12 hours of the forced expiratory volume in one second (FEV1 AUC0-12h)

    Time frame: after 6 weeks of each treatment

  2. Change in FEV1 AUC0-24h

    Time frame: after 6 weeks of each treatment

Secondary outcomes

  1. Change in FEV1 AUC12-24h

    Time frame: after 6 weeks of each treatment

  2. Change in AUC of the forced vital capacity (FVC AUC0-12h)

    Time frame: after 6 weeks of each treatment

  3. Change in FVC AUC0-24h

    Time frame: after 6 weeks of each treatment

  4. Change in FVC AUC12-24h

    Time frame: after 6 weeks of each treatment

  5. Change in peak FEV1 response

    Time frame: after 6 weeks of each treatment

  6. Change in trough FEV1 response

    Time frame: after 6 weeks of each treatment

  7. Change in peak FVC response

    Time frame: after 6 weeks of each treatment

  8. Change in trough FVC response

    Time frame: after 6 weeks of each treatment

  9. Individual FEV1measurements at each time point

    Time frame: up to 6 weeks

  10. Individual FVCmeasurements at each time point

    Time frame: up to 6 weeks

  11. Peak expiratory flow rate (PEFR)

    measured twice daily

    Time frame: weeks 4 to 6 of each treatment period

  12. Number of inhalations of rescue salbutamol therapy used per day

    Time frame: weeks 4 to 6 of each treatment period

  13. Assessment of daytime COPD symptom score rated on a 6-point rating scale

    Time frame: weeks 4 to 6 of each treatment period

  14. Assessment of nighttime COPD symptom score rated on a 5-point rating scale

    Time frame: weeks 4 to 6 of each treatment period

  15. Number of patients with adverse events

    Time frame: up to 23 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002 and a primary completion of Aug 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2014
First posted
Sep 12, 2014
Start
Feb 2002
Primary completionActual
Aug 2002
Last update
Sep 12, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02238119
Responsible party
Sponsor
First posted
Sep 12, 2014
Start date
Feb 2002
Primary completion
Aug 2002
Last update
Sep 12, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tiotropium · Formoterol

Start the discussion